Shares of The Cooper Cos. (NYSE:COO) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $183.49 and last traded at $182.92, with a volume of 96,275 shares. The stock had previously closed at $180.94.

A number of analysts have issued reports on COO shares. Jefferies Group raised The Cooper Cos. from a “hold” rating to a “buy” rating and set a $175.00 target price for the company in a research note on Friday, April 15th. Robert W. Baird reaffirmed a “buy” rating on shares of The Cooper Cos. in a research note on Tuesday, April 19th. Cleveland Research raised The Cooper Cos. from a “neutral” rating to a “buy” rating in a research note on Monday, May 16th. Wells Fargo & Co. reaffirmed a “hold” rating on shares of The Cooper Cos. in a research note on Friday, June 3rd. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of The Cooper Cos. in a research note on Saturday, June 4th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The Cooper Cos. presently has an average rating of “Buy” and a consensus target price of $167.00.

The company’s 50-day moving average price is $172.89 and its 200 day moving average price is $154.39. The stock has a market capitalization of $8.84 billion and a P/E ratio of 43.17.

The Cooper Cos. (NYSE:COO) last announced its quarterly earnings results on Thursday, June 2nd. The medical device company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.14. The company had revenue of $484.80 million for the quarter. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.72 EPS. On average, equities analysts anticipate that The Cooper Cos. will post $8.40 earnings per share for the current fiscal year.

The business also recently declared a semiannual dividend, which will be paid on Friday, August 5th. Stockholders of record on Friday, July 22nd will be given a dividend of $0.03 per share. This represents a dividend yield of 0.03%. The ex-dividend date is Wednesday, July 20th.

In related news, CEO Robert S. Weiss sold 151,839 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $163.02, for a total value of $24,752,793.78. Following the sale, the chief executive officer now directly owns 200,617 shares in the company, valued at approximately $32,704,583.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director A Thomas Bender sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $164.19, for a total value of $656,760.00. Following the completion of the sale, the director now owns 14,978 shares in the company, valued at $2,459,237.82. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in The Cooper Cos. by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,095 shares of the medical device company’s stock valued at $1,892,000 after buying an additional 68 shares in the last quarter. Gulf International Bank UK Ltd boosted its stake in The Cooper Cos. by 3.6% in the fourth quarter. Gulf International Bank UK Ltd now owns 14,531 shares of the medical device company’s stock valued at $1,950,000 after buying an additional 500 shares in the last quarter. Andra AP fonden boosted its stake in The Cooper Cos. by 8.8% in the fourth quarter. Andra AP fonden now owns 9,900 shares of the medical device company’s stock valued at $1,329,000 after buying an additional 800 shares in the last quarter. Century Capital Management LLC boosted its stake in The Cooper Cos. by 3.1% in the fourth quarter. Century Capital Management LLC now owns 131,227 shares of the medical device company’s stock valued at $17,611,000 after buying an additional 3,912 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in The Cooper Cos. by 2.7% in the fourth quarter. Principal Financial Group Inc. now owns 154,051 shares of the medical device company’s stock valued at $20,674,000 after buying an additional 4,043 shares in the last quarter.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.